EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Four Decades of Molecular Innovation in Chronic Myeloid Leukemia: From Antisense Targeting to Treatment-Free Remission

Maria Stefania De Propris, Alessandro Laganà iD, Massimo Breccia iD, Paolo De Fabritiis

Cancers · 12.06.2026 · 18 (12) · 1922

DOI: 10.3390/cancers18121922 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cancers, online erschienen am 12.06.2026. Verfasst von Maria Stefania De Propris und 3 weiteren Autor:innen. Beteiligte Einrichtung: Hematology, Department of Translational and Precision Medicine, Az. Policlinico Umberto I-Sapienza University, 00161 Rome, Italy. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 78 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Chronic myeloid leukemia (CML) represents a paradigm of targeted therapy, driven by the BCR::ABL1 fusion kinase. Over the past four decades, therapeutic strategies have evolved from early molecular targeting approaches and interferon-α to tyrosine kinase inhibitors (TKIs), dramatically improving survival and transforming CML into a largely controllable disease. To provide a comprehensive overview of this evolution, we conducted a narrative literature search across the PubMed and Embase databases, selecting peer-reviewed articles, international guidelines, and landmark clinical trials based on their historical and clinical relevance. Through this expert-driven synthesis, focusing on key milestones in CML therapy, including antisense strategies, interferon-based treatment, first-, second-, and third-generation TKIs, and the development of allosteric inhibitors, this paper analyzes current management strategies, treatment-free remission (TFR), and emerging therapies. The introduction of imatinib established proof of principle for oncogene-targeted therapy, leading to sustained survival improvements. Second- and third-generation TKIs further enhanced response depth and addressed resistance, including the T315I mutation. More recently, the development of the allosteric inhibitor asciminib introduced a novel mechanism of action and expanded therapeutic options for pretreated patients. Furthermore, the achievement of deep molecular responses has enabled TFR in approximately 40–60% of selected patients, redefining treatment goals toward functional cure. Emerging agents, including next-generation ATP-competitive and allosteric inhibitors, are showing promising activity in resistant disease and may further improve outcomes. Thus, CML represents a unique model of translational oncology, demonstrating how mechanistic insight can drive therapeutic innovation. Future strategies will focus on increasing TFR rates, overcoming resistance, targeting leukemic stem cells, and improving global access to therapy and monitoring, with the ultimate aim of achieving functional cure in the majority of patients.

Schlagwörter

Stichwörter der Autor:innen

BCR::ABL1 oncogenechronic myeloid leukemia (CML)treatment-free remissiontyrosine kinase inhibitors (TKIs)

Autor:innen und Institutionen

  • Hematology, Department of Translational and Precision Medicine, Az. Policlinico Umberto I-Sapienza University, 00161 Rome, Italy.
  • Department of Biomedicina e Prevenzione, Tor Vergata University, 00133 Rome, Italy.

ORCID-Profile: Alessandro Laganà, Massimo Breccia

Zitieren

APA

De Propris, M. S., Laganà, A., Breccia, M., & De Fabritiis, P. (2026). Four Decades of Molecular Innovation in Chronic Myeloid Leukemia: From Antisense Targeting to Treatment-Free Remission. Cancers, 18(12), 1922. https://doi.org/10.3390/cancers18121922

Vancouver

De Propris MS, Laganà A, Breccia M, De Fabritiis P. Four Decades of Molecular Innovation in Chronic Myeloid Leukemia: From Antisense Targeting to Treatment-Free Remission. Cancers. 2026;18(12):1922. doi:10.3390/cancers18121922

BibTeX
@article{DePropris2026,
  author = {De Propris, Maria Stefania and Laganà, Alessandro and Breccia, Massimo and De Fabritiis, Paolo},
  title = {Four Decades of Molecular Innovation in Chronic Myeloid Leukemia: From Antisense Targeting to Treatment-Free Remission},
  journal = {Cancers},
  year = {2026},
  volume = {18},
  number = {12},
  pages = {1922},
  doi = {10.3390/cancers18121922}
}
Kostenlos starten →